A retrospective comparison of aflibercept and ranibizumab in the management of macular oedema secondary to retinal vein occlusion

被引：0
|
作者：
Di Simplicio, Sandro [1 ]
Hogg, Jeff [1 ]
机构：
[1] Royal Victoria Infirm, Vitreoretinal Serv, Newcastle Upon Tyne, Tyne & Wear, England
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2018年 / 59卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
4259
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Aflibercept versus ranibizumab for cystoid macular oedema secondary to central retinal vein occlusion
    Karampelas, Michael
    Waxman, Jacob
    Barampouti, Foteini Faye
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [2] Real world clinical audit of aflibercept and ranibizumab use in the management of macular oedema secondary to central retinal vein occlusion
    Elatfy, Mohammed
    Than, Jonathan
    Palexas, George
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [3] Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion
    Hoy, Sheridan M.
    DRUGS & AGING, 2017, 34 (05) : 393 - 400
  • [4] Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion
    Sheridan M. Hoy
    Drugs & Aging, 2017, 34 : 393 - 400
  • [5] Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes
    Puche, Nathalie
    Glacet, Agnes
    Mimoun, Gerard
    Zourdani, Alain
    Coscas, Gabriel
    Soubrane, Gisele
    ACTA OPHTHALMOLOGICA, 2012, 90 (04) : 357 - 361
  • [6] Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab
    Vasileios Konidaris
    Zahra Al-Hubeshy
    Konstantinos T. Tsaousis
    Konstantina Gorgoli
    Somnath Banerjee
    Theodoros Empeslidis
    International Ophthalmology, 2018, 38 : 207 - 213
  • [7] Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab
    Konidaris, Vasileios
    Al-Hubeshy, Zahra
    Tsaousis, Konstantinos T.
    Gorgoli, Konstantina
    Banerjee, Somnath
    Empeslidis, Theodoros
    INTERNATIONAL OPHTHALMOLOGY, 2018, 38 (01) : 207 - 213
  • [8] Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab
    T D Papakostas
    L Lim
    T van Zyl
    J B Miller
    B S Modjtahedi
    C M Andreoli
    D Wu
    L H Young
    I K Kim
    D G Vavvas
    D D Esmaili
    D Husain
    D Eliott
    L A Kim
    Eye, 2016, 30 : 79 - 84
  • [9] Aflibercept in macular oedema secondary to retinal vein occlusion refractory to previous bevacizumab or ranibizumab: 48 week outcomes
    Spooner, Kimberly
    Fraser-Bell, Samantha
    Hong, Thomas
    Chang, Andrew
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2019, 47 : 155 - 156
  • [10] Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab
    Papakostas, T. D.
    Lim, L.
    van Zyl, T.
    Miller, J. B.
    Modjtahedi, B. S.
    Andreoli, C. M.
    Wu, D.
    Young, L. H.
    Kim, I. K.
    Vavvas, D. G.
    Esmaili, D. D.
    Husain, D.
    Eliott, D.
    Kim, L. A.
    EYE, 2016, 30 (01) : 79 - 84
12345